We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$153M
AUM Growth
+$25.8M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
76
New
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1 +$4.3M
2 +$3.79M
3 +$2.95M
4
PVLA
Palvella Therapeutics
PVLA
+$2.73M
5
ARWR icon
Arrowhead Research
ARWR
+$2.04M

Top Sells

Rank Stock Value
1 +$5.05M
2 +$4.62M
3 +$3.41M
4
AAOI icon
Applied Optoelectronics
AAOI
+$3.23M
5
ALMS
Alumis Inc
ALMS
+$2.85M

Sector Composition

Rank Sector Weight
1 Healthcare 63.9%
2 Energy 17.83%
3 Technology 7.89%
4 Consumer Discretionary 4.98%
5 Industrials 1.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$9.78B
$16.7M 10.93%
45,000
-15,477
TGTX icon
2
TG Therapeutics
TGTX
$7.44B
$13.8M 9.01%
251,025
+2,000
ABVX
3
Abivax
ABVX
$10.4B
$12.9M 8.45%
97,000
+26,100
CVX icon
4
Chevron
CVX
$394B
$12.4M 8.12%
75,000
XOM icon
5
ExxonMobil
XOM
$660B
$10.7M 7.01%
78,500
+8,500
ARWR icon
6
Arrowhead Research
ARWR
$12.3B
$8.97M 5.86%
110,100
+27,600
VKTX icon
7
Viking Therapeutics
VKTX
$3.87B
$8.16M 5.33%
209,300
CELC icon
8
Celcuity
CELC
$4.5B
$6.5M 4.25%
62,150
-29,525
NKTR icon
9
Nektar Therapeutics
NKTR
$2.5B
$6.23M 4.07%
89,300
+18,400
TSLA icon
10
Tesla
TSLA
$1.35T
$4.54M 2.97%
+10,800
CYTK icon
11
Cytokinetics
CYTK
$10.3B
$4.05M 2.64%
47,500
-17,000
ASTS icon
12
AST SpaceMobile
ASTS
$21.1B
$3.87M 2.53%
+43,500
PVLA
13
Palvella Therapeutics
PVLA
$2.24B
$3.44M 2.25%
+22,500
AMZN icon
14
Amazon
AMZN
$2.84T
$3.07M 2.01%
12,900
-20,100
NUVB icon
15
Nuvation Bio
NUVB
$2.16B
$2.95M 1.93%
520,000
+230,000
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.02B
$2.9M 1.89%
48,000
+14,500
ET icon
17
Energy Transfer Partners
ET
$72.4B
$2.54M 1.66%
133,100
BE icon
18
Bloom Energy
BE
$67.8B
$2.27M 1.48%
7,500
+3,000
FCX icon
19
Freeport-McMoran
FCX
$93.3B
$2.04M 1.34%
32,500
-6,000
NBIS
20
Nebius Group N.V.
NBIS
$74.2B
$1.88M 1.23%
+6,800
ALMS
21
Alumis Inc
ALMS
$3.18B
$1.45M 0.95%
51,600
-122,650
AMBA icon
22
Ambarella
AMBA
$3.58B
$1.37M 0.9%
+16,000
CBRS
23
Cerebras Systems
CBRS
$48.7B
$1.24M 0.81%
+5,600
DFTX
24
Definium Therapeutics
DFTX
$5.66B
$1.18M 0.77%
+25,000
NOK icon
25
Nokia
NOK
$59.4B
$1.09M 0.71%
+82,000

Similar funds

ACT Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ACT Capital Management held 76 positions worth $153M, up 20% from $127M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

ACT Capital Management deployed $5.34M of net new capital in Q2 2026, opening 20 new positions and adding to 15 existing holdings. Its largest new stake was Tesla: 10,800 shares worth $4.54M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 62% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was Amazon, an estimated $5.05M trimmed.

  • ACT Capital Management's largest Q2 2026 buy was Tesla: 10,800 shares worth $4.54M.
  • ACT Capital Management added most to Abivax in Q2 2026, an estimated $2.95M increase.
  • ACT Capital Management's biggest Q2 2026 reduction was Amazon, cutting an estimated $5.05M.
  • ACT Capital Management fully exited STAAR Surgical in Q2 2026, selling an estimated $1.04M.
  • ACT Capital Management's ten largest holdings make up 66% of its $153M portfolio in Q2 2026.
  • ACT Capital Management opened 20 new positions and closed 14 in Q2 2026.
  • ACT Capital Management's portfolio value rose 20% quarter-over-quarter to $153M.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.